

Table 8.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1998 to 2007
Recipients with Kidney-Pancreas Transplants

	Year of Transplant									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
Transplants	972	941	915	891	905	871	881	903	924	862
Tx with Antirejection Treatments	286	260	232	194	191	153	127	118	107	93
Antibodies										
Any in Category	44.4%	42.3%	41.4%	32.0%	50.8%	58.2%	63.0%	50.8%	49.5%	51.6%
Atgam/NRATG/NRATS	10.1%	6.5%	3.9%	0.5%	2.6%	2.0%	3.1%	2.5%	2.8%	0.0%
OKT3	35.7%	24.6%	22.8%	12.4%	10.5%	9.8%	11.8%	11.0%	6.5%	9.7%
Thymoglobulin	3.1%	16.2%	15.1%	20.6%	34.0%	39.9%	44.1%	39.0%	34.6%	37.6%
Zenapax	1.7%	1.5%	1.7%	1.0%	4.7%	11.8%	7.1%	7.6%	9.3%	9.7%
Simulect	0.0%	0.4%	2.2%	0.5%	1.0%	1.3%	1.6%	0.0%	0.9%	0.0%
Campath	0.0%	0.0%	0.0%	0.0%	0.5%	3.9%	2.4%	0.0%	0.0%	2.2%
Corticosteroids										
Any in Category	77.6%	80.8%	82.8%	87.1%	76.4%	68.6%	68.5%	71.2%	68.2%	67.7%
Steroids	77.6%	80.8%	82.8%	87.1%	76.4%	68.6%	68.5%	71.2%	68.2%	67.7%
Antimetabolites										
Any in Category	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.9%	0.0%
Cytosan	0.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Methotrexate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.9%	0.0%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.